Core Insights - The article discusses significant developments in the pharmaceutical and healthcare industry, including leadership changes, regulatory approvals, and strategic collaborations aimed at enhancing treatment options for patients with complex conditions like brain metastases [14][4][12]. Policy Developments - The National Medical Products Administration (NMPA) is focusing on balancing safety and development, emphasizing the importance of legal administration and scientific regulation to protect the legitimate rights of enterprises and promote high-quality industry development [2]. Drug Approvals - Yuandong Biotech received a drug registration certificate for Brivaracetam tablets, marking it as the first generic drug approved under the new registration classification in China. The expected sales for the original drug are approximately 160,000 yuan in the first half of 2025 [4]. - Jiutian Pharmaceutical has received approval for clinical trials of JMHT06 for treating acute gouty arthritis [5]. Capital Market Activities - L'Oréal plans to increase its stake in Galderma by acquiring an additional 10% of shares, which will raise its total ownership to 20% by early 2026. This move includes the nomination of two non-independent directors from L'Oréal to Galderma's board [7]. Industry Collaborations - Baiyang Pharmaceutical is collaborating with multiple medical institutions to enhance treatment for brain metastases, including launching real-world studies with ZAP-X technology and establishing a precision radiotherapy center [12][9].

Group 1 - The company announced the resignation of its chairman, CEO, and other key positions, effective December 7, 2025, with the board expressing respect for the decision and gratitude for contributions made during the tenure [1] - David McKee HAND has been appointed as the new chairman, and the board has initiated a search for a new CEO, considering both internal and external candidates [1] - The company assures that these leadership changes will not affect its existing strategies and daily operations, with a commitment to continue stable development [1] Group 2 - Since its establishment in 2015, the former CEO has focused on the long-term development and strategic layout of the company, leading it through a significant transformation in the pharmaceutical industry [2] - The company successfully transitioned from a pharmaceutical e-commerce platform to a leading enterprise in "AI + chronic disease management," and it went public on the Hong Kong Stock Exchange in 2024 [2] - The company aims to continue focusing on online chronic disease management, leveraging AI services to assist millions of patients and contributing to the "Healthy China 2030" initiative [2]

Core Viewpoint - Ark Health Holdings Limited announced the resignation of Mr. Xie Fangmin as Chairman, CEO, and authorized representative effective December 7, 2025, to focus on personal matters, while he will continue to provide guidance as a non-executive director [1][2] Group 1: Leadership Changes - Mr. David McKee Hand has been appointed as the new Chairman effective December 7, 2025, following Mr. Xie Fangmin's resignation [1] - The board has initiated a formal search for a new CEO, considering both internal and external candidates to ensure a suitable successor [1] Group 2: Contributions and Future Direction - Mr. Xie Fangmin has been instrumental in the company's long-term development since its founding in 2015, introducing the "H2H (Hospital to Home)" model and integrating AI with healthcare [2] - Under his leadership, the company transitioned from a pharmaceutical e-commerce platform to a leading "AI + chronic disease management" enterprise, successfully listing on the Hong Kong Stock Exchange in 2024 [2] - The company aims to continue focusing on online chronic disease management, leveraging AI to serve millions of patients and contribute to the "Healthy China 2030" initiative [2]

Core Viewpoint - Ark Health Holdings Limited announced the resignation of Mr. Xie Fangmin as Chairman, CEO, and other positions effective December 7, 2025, to focus on personal matters, while he will continue to provide guidance as a non-executive director [1][2] Group 1: Leadership Changes - Mr. Xie Fangmin's resignation is respected by the board, which appreciates his significant contributions during his tenure [1] - David McKee Hand has been appointed as the new Chairman effective December 7, 2025, while the board will search for a new CEO from both internal and external candidates [1] Group 2: Company Strategy and Future Direction - Since its establishment in 2015, Mr. Xie has focused on the long-term development of the company, introducing the "H2H (Hospital to Home)" model and integrating AI with healthcare [2] - The company has transitioned from a pharmaceutical e-commerce platform to a leading "AI + chronic disease management" enterprise, successfully listing on the Hong Kong Stock Exchange in 2024 [2] - The company aims to continue focusing on online chronic disease management and building a win-win ecosystem for chronic disease services, contributing to the "Healthy China 2030" goal [2]

Core Viewpoint - Ark Health (06086.HK) announced the resignation of its Chairman, CEO, and other key positions, with new appointments effective from December 7, 2025 [1] Group 1 - Xie Fangmin has resigned from the positions of Chairman, Chairman of the Nomination Committee, CEO, and Authorized Representative [1] - Xie Fangmin has been reappointed as a Non-Executive Director [1] - David McKee HAND has been appointed as the new Chairman [1] Group 2 - ZHOU Feng and David McKee HAND have been appointed as members of the Nomination Committee [1] - Zhu Xiaolu has been appointed as the Chairman of the Nomination Committee [1] - Zou Yuming has been appointed as the Authorized Representative [1]

（於開曼群島註冊成立的有限公司） （股份代號：6086） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 方 舟 雲 康 控 股 有 限 公 司（「本公司」）的 董 事 會（「董事會」）成 員 載 列 如 下： ZHOU Feng先 生 （執行董事） 鄒宇鳴先生 （執行董事） David McKee HAND先 生 （董事會主席及非執行董事） 謝方敏先生 （非執行董事） 王海忠博士 （獨立非執行董事） 康韋女士 （獨立非執行董事） 朱小路先生 （獨立非執行董事） 三個董事委員會各自的成員組成載於下表： 董事名單及其角色與職能 | | 董事委員會 | | | | | | --- | --- | --- | --- | --- | --- | | 董 事 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | | 生 ZHOU Feng先 | | | | 成 | 員 | | 鄒宇鳴先生 | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不作任何聲明，並明確表示概不就因本公告的全部或任何部分內容而 產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 主席、首席執行官及授權代表變更； 董事重新委任； 及 提名委員會組成變更 方舟云康控股有限公司（「本公司」，連同其附屬公司及合併關聯實體， 「本集團」）董事（「董事」，各自為一名「董事」）會（「董事會」）謹此公 告， –1– 於本公告日期，根據證券及期貨條例（香港法例第571章）第XV部的規定，謝 先生於本公司合共711,449,830股股份中擁有權益。 除上述披露者外，於本公告日期，謝先生(i)在過往三年內並無在香港或海外 任何其他證券市場上市之公眾公司中擔任任何董事職位；(ii)並無其他主要 任命及資格；(iii)在本集團內並無擔任任何其他職位；(iv)與本公司任何其他 董事、高級管理人員或主要或控制股東並無任何關係；及(v)在證券及期貨 條例（香港法例第571章）第XV部的定義下，在本公司股份 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06086 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,340,267,457 | | 0 | | 1,340,267,457 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 1,340,267,457 | | 0 | | 1,340,267,457 | 公司名稱: 方舟云康控股有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本 ...

Core Viewpoint - The collaboration between Ark Health and Tencent Health marks a new development phase in the domestic chronic disease management sector, providing comprehensive support for technological validation, scenario implementation, and large-scale deployment in the industry [1][5]. Group 1: AI and Chronic Disease Management - The "AI + Chronic Disease Management" solution is based on Ark Health's effective practices in the field, demonstrating significant value through substantial business data, with a 2.4 times increase in AI function experience user volume in October [1][2]. - The AI technology effectively addresses user pain points, such as the common difficulty patients face in understanding medical reports, leading to increased user engagement and trust in the AI functionalities [2][3]. Group 2: Technical Foundation and Security Measures - The solution is built on a solid technical foundation, utilizing Tencent Health's TI platform to create a large model base, enabling efficient fine-tuning and continuous optimization of models [3][4]. - Ark Health has implemented multiple security measures to ensure reliable application in the sensitive medical field, including knowledge base optimization and compliance upgrades to mitigate risks associated with large models [2][3]. Group 3: Industry Collaboration and Policy Response - The partnership aims to integrate Ark Health's AI capabilities with Tencent Health's comprehensive service capabilities, facilitating safe, efficient, and compliant digital upgrades for industry partners [3][5]. - This collaboration aligns with recent policy initiatives from the National Health Commission and other departments to promote and regulate the application of AI in healthcare, positioning AI medical solutions as a vital component of public health infrastructure [5]. Group 4: Future Outlook - Ark Health plans to continue driving technological innovation and deepen collaborations with Tencent Health and other industry partners, aiming to enhance chronic disease management services towards greater efficiency, precision, and accessibility [5].

Core Insights - The collaboration between Ark Health (方舟健客) and Tencent Health marks a new development stage in chronic disease management in China, providing comprehensive support from technology validation to large-scale deployment [1] - The "AI + Chronic Disease Management" solution is based on Ark Health's effective practices and significant business data, showcasing a 2.4 times increase in AI feature user engagement in October [2] - The partnership aims to integrate Ark Health's AI capabilities with Tencent Health's robust service infrastructure to facilitate safe, efficient, and compliant digital upgrades in the healthcare industry [4][5] Group 1 - The "AI + Chronic Disease Management" solution is designed to address real user pain points, such as understanding medical reports, significantly increasing user engagement and trust in AI functionalities [2][3] - Ark Health's AI + H2H ecosystem, which includes a self-developed large model, provides a closed-loop service system covering the entire chronic disease management cycle [3] - The collaboration is a response to national policies promoting the integration of AI in healthcare, aiming to contribute to the "Healthy China 2030" strategy [6] Group 2 - The solution leverages Ark Health's deep understanding of internet medical service scenarios and Tencent Health's stable and secure technical infrastructure [5] - The partnership emphasizes the importance of safety and compliance, utilizing Tencent Health's intelligent security measures to protect sensitive data in medical applications [4] - Future plans include continued technological innovation and collaboration with industry partners to enhance chronic disease management services [6]